Abstract
Introduction

Pulmonary toxicity by cytotoxic agents, in theory, falls into three categories according to the mechanisms involved. The first one relates to direct tissue damage by agents, the second one is due to abnormal inflammatory cytokine induction or suppression by the agent's original function or via the effect of cytotoxicity, and the final one is by allergic reaction to agents (1, 2). Now, a majority of the pulmonary toxicity cases caused by cytotoxic agents are considered a consequence of a combination of the three mechanisms. For example, pulmonary toxicity by bleomycin is initiated by pulmonary vascular endothelial cell damage, followed by imbalance of cytokines and adhesion molecules, resulting in severe damage to the alveolar epithelium and interstitium (3). S-1 is a recently approved oral anti-neoplastic agent composed of three components, tegafur, 5-C-2, 4-dihydroxypyridine (CDHP), and potassium oxonate (Oxo
F i g u r e 1 . ( A) HRCT o n a d mi s s i o n s h o we d d i f f u s e a r e t i c u l a r s h a d o w a n d g r o u n d g l a s s o p a c i t y p r e d o mi n a n t l y a t s u b p l e u r a l l e s i o n s . ( B ) T h e l e s i o n s we r e d r a ma t i c a l l y r e s o l v e d 7 d a y s a f t e r c o r t i c o s t e r o i d t r e a t me n t .
F i g u r e 2 . S p e c i me n o f t r a n s b r o n c h i a l l u n g b i o p s y s h o we d mo d e r a t e l y mp h o c y t e i n f i l t r a t i o n i n t h e p u l mo n a r y i n t e rs t i t i u m wi t h f i b r o -e d e ma t o u s t h i c k e n i n g a n d mi l d v a s c u l i t i s . Gr a n u l o ma f o r ma t i o n ( a r r o w) wa s a l s o s e e n ( HE , o r i g i n a l ma g n i f i c a t i o n : × 1 0 ) .
. (Fig. 1B) . Also, alveolar-arterial oxygen gradient (A-aDO2) was significantly decreased from 64.2 to 40.8 torr, and predicted diffusing capacity was increased from 32.5 to 60.3% after treatment (Fig. 4) . 1 we r e a l s o e x a mi n e d  s e p a r a t e l y . E a c h a g e n t , d i v e r s e l y d i l u t e d f r o Cl i n i c a l c o u r s e . I n t e r s t i t i a l p n e u mo n i a i n d u c e d  b y S -1 d r a ma t i c a l l y r e s p o n d e d t o c o r t i c o s t e r o i d t h e r a p (13, 14) . As the use of S-1 becomes more common, the incidence of S-1 related pulmonary toxicity may also increase. All clinicians should be aware that S-1 has the potential to cause lung injury.
Taken together, a diagnosis of drug-induced lung injury was established. By the time of the diagnosis, S-1 and rabeprazole had been discontinued, although hypoxia and fever were still present. High-dose corticosteroid (500 mg of methylprednisolone) was initiated intravenously for three consecutive days followed by oral prednisone (1 mg/kg/day). Seven days after treatment, both his symptoms and radiographic findings were dramatically resolved
Discussion
Most antineoplastic drugs have the potential to induce pulmonary toxicity, involving lung parenchyma, airways, pleura, and pulmonary circulation (8). The mainstay of treatment of drug-induced pneumonia is to identify and remove the causative agent as soon as possible. However, diagnosis is often difficult due to the patient's confounding factors, i.e. pulmonary co-morbidities and other modalities such as concomitant chemotherapy and radiation therapy (9).
F i g u r e 3 . Re s u l t s o f DL S T wi t h d r u g s a d mi n i s t e r e d t o t h e p a t i e n t . T h e t h r e e c o mp o n e n t s o f S -
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f o l d o f t h e o r i g i n a l c o n c e n t r a t i o n ( i n d i c a t e d i n t h e f i g u r e ) , wa s a d d e d t o c u l t u r e me d i u m c o n t a i n i n g t h e p a t i e n t ' s p e r i p h e r a l l y mp h o c y t e s . No t e t h a t t h e t e s t s wi t h t e g a f u r a n d S -1 p r ov i d e d p o s i t i v e r e s u l t s a t mu l t i p l e d i l u t i o n p o i n t s . T h e f i g u r e a l s o i n d i c a t e s t h e l e v e l o f n e g a t i v e c o n t r o l a n d t h r e s h o l d f o r j u d g i n g a s p o s i t i v e .
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